A REVIEW OF REAL-WORLD EVIDENCE IN NON-ONCOLOGY SUBMISSIONS MADE TO FOUR HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES

被引：0
|
作者：
Balijepalli, C. [1 ]
Li, J. [1 ]
Ferrazzi, S. [2 ]
Mathers, E. [3 ]
Gullapalli, L. [1 ]
Awan, A. [3 ]
机构：
[1] Pharmalyt Grp, Vancouver, BC, Canada
[2] PharmaAccess, Waterdown, ON, Canada
[3] AbbVie Corp, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA50
引用
下载
收藏
页码：S253 / S254
页数：2
相关论文
共 50 条
  • [11] THE VALUE OF REAL-WORLD EVIDENCE (RWE) IN MELANOMA IN HEALTH TECHNOLOGY ASSESSMENT (HTA) APPRAISALS
    Shah, R.
    Gautam, R.
    Rai, M. K.
    Prasanna, R.
    VALUE IN HEALTH, 2022, 25 (12) : S317 - S317
  • [12] HEALTH TECHNOLOGY ASSESSMENT (HTA) CASE STUDIES: COMPARING ACCEPTABILITY OF REAL-WORLD EVIDENCE (RWE) IN APPRAISALS FOR ONCOLOGY MEDICINES
    Zong, J.
    Pan, X.
    Rojubally, A.
    Jiao, X.
    Bruno, A.
    Bergeson, J. Gdovin
    VALUE IN HEALTH, 2023, 26 (12) : S321 - S321
  • [13] COMPARISON OF THE USE OF REAL-WORLD EVIDENCE (RWE) BY HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES IN REVIEWS OF DRUGS FOR RARE DISEASES (DRDS)
    Kirby, J.
    Tadros, N.
    Gosain, S.
    VALUE IN HEALTH, 2023, 26 (12) : S508 - S508
  • [14] HEALTH TECHONOLGY ASSESSMENT (HTA) AGENCIES CONSIDERATION OF REAL WORLD EVIDENCE (RWE)
    Jao, R.
    Jaksa, A.
    Pontynen, A.
    Wang, X.
    VALUE IN HEALTH, 2018, 21 : S7 - S7
  • [15] GLOBAL USE OF NORDIC REAL-WORLD EVIDENCE: A SYSTEMATIC REVIEW OF PUBLISHED LITERATURE AND HTA SUBMISSIONS
    Kaushik, P.
    Grip, Toresson E.
    Lueza, B.
    Arya, S.
    Singh, N.
    Nanda, S.
    Grover, R.
    Afaque, A.
    Syal, K.
    VALUE IN HEALTH, 2023, 26 (12) : S531 - S531
  • [16] THE USE OF EXPERT OPINIONS, PATIENT, AND CARER PERSPECTIVES AND REAL-WORLD EVIDENCE IN ORPHAN DISEASE SUBMISSIONS DIFFERS FOR HEALTH TECHNOLOGY ASSESSMENT AGENCIES ACROSS THE WORLD
    Taieb, Ben A.
    Withers, K.
    Hardy, E. J.
    Swart, N.
    Redhead, G.
    Lang, S. H.
    Foy, C. F.
    Leadley, R. M.
    Swift, S. L.
    VALUE IN HEALTH, 2023, 26 (12) : S325 - S325
  • [17] EVALUATION OF REAL-WORLD EVIDENCE (RWE) USED WITHIN HEALTH TECHNOLOGY ASSESSMENTS (HTA) IN ONCOLOGY WITH PIVOTAL SINGLE-ARM TRIALS: A COMPARATIVE STUDY OF SIX HTA AGENCIES
    Harricharan, S.
    Gurjar, K.
    Nguyen, K.
    Forsythe, A.
    VALUE IN HEALTH, 2021, 24 : S51 - S51
  • [18] GLOBAL ONCOLOGY ACCESS - THE RELATIVE DIFFICULTY OF REIMBURSEMENT ACROSS FOUR HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES
    Nguyen, K.
    Forsythe, A.
    Azimpour, K.
    Vu, B. K.
    Tomaras, D.
    VALUE IN HEALTH, 2020, 23 : S68 - S68
  • [19] REAL-WORLD EVIDENCE (RWE) TO SUPPORT REGULATORY SUBMISSIONS: LANDSCAPE ASSESSMENT & REVIEW
    Haris, G.
    Acha, V
    Liu, S.
    Burcu, M.
    VALUE IN HEALTH, 2023, 26 (06) : S213 - S213
  • [20] USING REAL-WORLD EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS: LESSONS AND INSIGHTS FROM REVIEW OF NICE'S TECHNOLOGY ASSESSMENT REPORTS (2016-2017)
    Aggarwal, S.
    Topaloglu, O.
    Kumar, S.
    VALUE IN HEALTH, 2018, 21 : S7 - S7
12345